<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="22917">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02808442</url>
  </required_header>
  <id_info>
    <org_study_id>UCART19_02</org_study_id>
    <secondary_id>2015-004293-15</secondary_id>
    <nct_id>NCT02808442</nct_id>
  </id_info>
  <brief_title>Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia</brief_title>
  <acronym>PALL</acronym>
  <official_title>A Phase 1, Open Label, Non-comparative, Monocenter Study to Evaluate the Safety and the Ability of UCART19 to Induce Molecular Remission in Paediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukaemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Recherches Internationales Servier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Servier</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims at evaluating the safety and ability of UCART19 to induce molecular
      remission in pediatric patients with relapsed or refractory CD19-positive B-cell acute
      lymphoblastic leukemia (B-ALL) ahead of planned allogeneic hematopoietic stem cell
      transplantation (allo-HSCT).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and Severity of Adverse Events</measure>
    <time_frame>From inclusion to Day 84 post UCART19 infusion or until the initiation of allo-HSCT conditioning regimen</time_frame>
    <description>Adverse events assessed according to NCI-CTCAE v4.0 criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and Severity of Adverse Events</measure>
    <time_frame>From Day 85 or the initiation of allo-HSCT conditioning regimen to Month 15</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Molecular Remission Rate</measure>
    <time_frame>At Day 28 post UCART19 infusion</time_frame>
    <description>Proportion of patients in whom a Molecular Remission, as defined by National Comprehensive Cancer Network (NCCN) guideline, will be achieved</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Refractory B-cell Acute Lymphoblastic Leukemia</condition>
  <condition>Relapsed B-cell Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>UCART19</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>UCART19</intervention_name>
    <arm_group_label>UCART19</arm_group_label>
    <other_name>S68587</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with relapsed or refractory CD19-positive B-acute lymphoblastic leukaemia
             (B-ALL)

               1. who have exhausted available treatment options

               2. eligible for allo-HSCT with suitable donor available

          -  Estimated life expectancy â‰¥ 12 weeks

          -  Considered medically fit for allo-HSCT

          -  Eastern Cooperative Oncology Group (ECOG) performance status &lt; 2

        Exclusion Criteria:

          -  Burkitt leukemia

          -  CD19-negative B-cell leukemia

          -  Uncontrolled Central Nervous System (CNS) leukemia

          -  Active acute or chronic Graft-versus-Host Disease (GvHD)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Waseem Qasim, MRCP, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCL, Great Ormond Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Institut de Recherches Internationales Servier</last_name>
    <phone>+33 1 55 72 43 66</phone>
    <email>clinicaltrials@servier.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCL Great Ormond Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <lastchanged_date>June 20, 2016</lastchanged_date>
  <firstreceived_date>June 16, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Burkitt Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
